Citius Pharma receives Nasdaq delisting determination for bid price non-compliance; plans hearing

Citius Pharmaceuticals, Inc.

Received delisting determination on Sept 10, 2024 after failing to regain $1.00 bid price compliance by extended deadline of Sept 9, 2024.
Company will request hearing before Nasdaq Hearing Panel, which automatically stays suspension/delisting pending outcome.
Panel may grant additional extension of up to 180 days from delisting letter date to regain compliance.
No assurance that relief or continued listing will be granted. Stock trades on Nasdaq Capital Market under CTXR.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.